Navi Mumbai, India

Rajesh Kumar Dwivedi


 

Average Co-Inventor Count = 8.8

ph-index = 1


Company Filing History:


Years Active: 2016-2019

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: **Rajesh Kumar Dwivedi: Innovator in Pharmaceutical Processes**

Introduction

Rajesh Kumar Dwivedi, based in Navi Mumbai, India, is a notable inventor in the pharmaceutical industry with a focus on innovative processes for drug preparation. With two patents to his name, he has made significant contributions to the development of therapeutics.

Latest Patents

Rajesh's most recent patents include:

1. **Process for the Preparation of Apremilast** - This invention pertains to a method for synthesizing apremilast, a medication used to treat inflammatory conditions. The patent also covers a p-xylene solvate of apremilast and the process involved in its preparation.

2. **Amides of 2-Amino-4-Arylthiazole Compounds and Their Salts** - This disclosure presents a novel approach to the salts of N-{4-[2,4-difluoro-3-(trifluoromethyl)phenyl]-1,3-thiazol-2-yl}dimethyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-5-yl)acetamide, along with the process for their synthesis.

Career Highlights

Rajesh has had an impressive career with significant roles at Glenmark Life Sciences Limited and Glenmark Pharmaceuticals S.A. His work in these companies has allowed him to apply his innovative ideas to the real-world challenges in pharmaceutical development, leading to his recent patented inventions.

Collaborations

Throughout his career, Rajesh has collaborated with talented individuals such as Suresh Mahadev Kadam and Sachin Baban Gavhane. These collaborations have further enriched his experience and contributed to the development of significant pharmaceutical processes.

Conclusion

Rajesh Kumar Dwivedi exemplifies innovation in the pharmaceutical sector with his groundbreaking patents and collaborations. His contributions not only reflect his expertise but also significantly advance the field of drug development, aiming to improve therapeutic options for patients worldwide.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…